The emerging role of anti‐CD25 directed therapies as both immune modulators and targeted agents in cancer

No abstract is available for this paper.

• Publication year

  2017

• Venue

  British Journal of Haematology

• Publication date

  2017-05-30

• Fields of study

  Medicine

• Identifiers
  DOI 10.1111/bjh.14770PMID 28556984
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Treatment of Metastatic Melanoma

  2018cited by this paper
• Fc-Optimized Anti-CD25 Depletes Tumor-Infiltrating Regulatory T Cells and Synergizes with PD-1 Blockade to Eradicate Established Tumors

  2017cited by this paper
• B cell regulation of the anti-tumor response and role in carcinogenesis

  2016cited by this paper
• Human regulatory T cells suppress proliferation of B lymphoma cells

  2016cited by this paper
• Regulatory T cells in cancer immunotherapy

  2016influential reference
• Design and Synthesis of Tesirine, a Clinical Antibody-Drug Conjugate Pyrrolobenzodiazepine Dimer Payload.

  2016cited by this paper
• Combining antibody-drug conjugates and immune-mediated cancer therapy: What to expect?

  2016cited by this paper
• Toxicity and outcome of anti-GD2 antibody ch14.18/CHO in front-line, high-risk patients with neuroblastoma: Final results of the phase III immunotherapy randomisation (HR-NBL1/SIOPEN trial).

  2016cited by this paper
• Assessing the impact of multiple sclerosis disease activity and daclizumab HYP treatment on patient-reported outcomes: Results from the SELECT trial.

  2016cited by this paper
• ADCT-301, a Pyrrolobenzodiazepine (PBD) Dimer–Containing Antibody–Drug Conjugate (ADC) Targeting CD25-Expressing Hematological Malignancies

  2016cited by this paper
• Immunotoxin therapy for hematologic malignancies: where are we heading?

  2016cited by this paper
• Hemophagocytic syndromes (HPSs) including hemophagocytic lymphohistiocytosis (HLH) in adults: A systematic scoping review.

  2016cited by this paper
• Tumor Cells Chronically Treated with a Trastuzumab–Maytansinoid Antibody–Drug Conjugate Develop Varied Resistance Mechanisms but Respond to Alternate Treatments

  2015cited by this paper
• 90Y-daclizumab, an anti-CD25 monoclonal antibody, provided responses in 50% of patients with relapsed Hodgkin’s lymphoma

  2015influential reference
• Tuning IL-2 signaling by ADP-ribosylation of CD25

  2015cited by this paper
• Complete Remissions of Adult T-cell Leukemia with Anti-CD25 Recombinant Immunotoxin LMB-2 and Chemotherapy to Block Immunogenicity

  2015cited by this paper
• Anticancer immunotherapy by CTLA-4 blockade: obligatory contribution of IL-2 receptors and negative prognostic impact of soluble CD25

  2015cited by this paper
• CD25 (IL2RA) Orchestrates Negative Feedback Control and Stabilizes Oncogenic Signaling Strength in Acute Lymphoblastic Leukemia

  2015cited by this paper
• FOXP3+ regulatory T cells and their functional regulation

  2015cited by this paper
• CD30 Downregulation, MMAE Resistance, and MDR1 Upregulation Are All Associated with Resistance to Brentuximab Vedotin

  2015cited by this paper
• A Dose Finding Lead-in Study of E7777 (Diphtheria toxin fragment-Interleukin-2 Fusion Protein) in Persistent or Recurrent Cutaneous T-Cell Lymphoma (CTCL)

  2014cited by this paper
• Daclizumab (anti-CD25) in multiple sclerosis.

  2014cited by this paper
• The role of tumor-associated macrophages on serum soluble IL-2R levels in B-cell lymphomas.

  2014cited by this paper
• Immune Monitoring of the Circulation and the Tumor Microenvironment in Patients with Regionally Advanced Melanoma Receiving Neoadjuvant Ipilimumab

  2014cited by this paper
• PIM inhibitors target CD25-positive AML cells through concomitant suppression of STAT5 activation and degradation of MYC oncogene.

  2014cited by this paper
• Monitoring the frequency and function of regulatory T cells and summary of the approaches currently used to inhibit regulatory T cells in cancer patients.

  2014cited by this paper
• Immunotoxins for leukemia.

  2014cited by this paper
• Regulatory T cells in cancer immunotherapy.

  2014cited by this paper
• Advances in the treatment of hematologic malignancies using immunoconjugates.

  2014influential reference
• In Vivo Maintenance of Human Regulatory T Cells during CD25 Blockade

  2014cited by this paper
• Reduction of Regulatory T Cells by Mogamulizumab, a Defucosylated Anti-CC Chemokine Receptor 4 Antibody, in Patients with Aggressive/Refractory Mycosis Fungoides and Sézary Syndrome

  2014cited by this paper
• The relationship between lymphocyte subsets and clinico-pathological determinants of survival in patients with primary operable invasive ductal breast cancer

  2013cited by this paper
• Clinical Significance of sIL-2R Levels in B-Cell Lymphomas

  2013cited by this paper
• Association of circulating regulatory T cell number with the incidence and prognosis of diffuse large B‐cell lymphoma

  2013cited by this paper
• Functional polymorphism rs7072793 C > T affect individual susceptibility to breast cancer by modulating CD25 transcription activity

  2013cited by this paper
• CD25 expression status improves prognostic risk classification in AML independent of established biomarkers: ECOG phase 3 trial, E1900.

  2012influential reference
• The role of interleukin-2 during homeostasis and activation of the immune system

  2012influential reference
• Early relapse is associated with high serum soluble interleukin-2 receptor after the sixth cycle of R-CHOP chemotherapy in patients with advanced diffuse large B-cell lymphoma.

  2012influential reference
• Integrative epigenomic analysis identifies biomarkers and therapeutic targets in adult B-acute lymphoblastic leukemia.

  2012cited by this paper
• Exploiting a natural conformational switch to engineer an Interleukin-2 superkine

  2012cited by this paper
• Prognostic index for acute- and lymphoma-type adult T-cell leukemia/lymphoma.

  2012cited by this paper
• Multipeptide immune response to cancer vaccine IMA901 after single-dose cyclophosphamide associates with longer patient survival

  2012cited by this paper
• Tumor-evoked regulatory B cells promote breast cancer metastasis by converting resting CD4⁺ T cells to T-regulatory cells.

  2011cited by this paper
• Dendritic Cell Vaccination in Combination with Anti-CD25 Monoclonal Antibody Treatment: A Phase I/II Study in Metastatic Melanoma Patients

  2010cited by this paper
• Identification of Therapeutic Targets for Quiescent, Chemotherapy-Resistant Human Leukemia Stem Cells

  2010cited by this paper
• Anti-GD2 antibody with GM-CSF, interleukin-2, and isotretinoin for neuroblastoma.

  2010cited by this paper
• The architectural pattern of FOXP3-positive T cells in follicular lymphoma is an independent predictor of survival and histologic transformation.

  2010cited by this paper
• Clinical Cancer esearch cer Therapy : Clinical dritic Cell Vaccination in Combination with Anti-CD 25 oclonal Antibody Treatment : A Phase I / II Study in R astatic Melanoma Patients

  2010cited by this paper
• Genome-wide association study meta-analysis identifies seven new rheumatoid arthritis risk loci

  2010cited by this paper
• CD25 Appears Non Essential for Human Peripheral Treg Maintenance In Vivo

  2010cited by this paper
• Influence of Serum and Soluble CD25 (sCD25) on Regulatory and Effector T‐cell Function in Hepatocellular Carcinoma

  2010cited by this paper
• Structural basis of immunosuppression by the therapeutic antibody daclizumab

  2010cited by this paper
• Characterization of regulatory T cells in patients with dermatomyositis.

  2010cited by this paper
• A Phase I Clinical Trial of CHT-25 a 131I-Labeled Chimeric Anti-CD25 Antibody Showing Efficacy in Patients with Refractory Lymphoma

  2009cited by this paper
• Analysis of human T-cell lymphotropic virus in CD25+ anaplastic large cell lymphoma in children.

  2009cited by this paper
• Interleukin-2 receptor alpha-chain (CD25) expression on leukaemic blasts is predictive for outcome and level of residual disease in AML.

  2009cited by this paper
• Appraisal of immune response in lymphoproliferative syndromes: a systematic review.

  2009cited by this paper
• Systemic mastocytosis in 342 consecutive adults: survival studies and prognostic factors.

  2009cited by this paper
• FcγRIIIa polymorphisms and cetuximab induced cytotoxicity in squamous cell carcinoma of the head and neck

  2009cited by this paper
• Immunoglobulin G fragment C receptor polymorphisms and clinical efficacy of trastuzumab-based therapy in patients with HER-2/neu-positive metastatic breast cancer.

  2008cited by this paper
• Interleukin-2 receptor downstream events in regulatory T cells: Implications for the choice of immunosuppressive drug therapy

  2008cited by this paper
• Treatment of Metastatic Melanoma Using Interleukin-2 Alone or in Conjunction with Vaccines

  2008cited by this paper
• Serum soluble interleukin 2 receptor alpha in human cancer of adults and children: a review.

  2008cited by this paper
• Correlation of high numbers of intratumoral FOXP3+ regulatory T cells with improved survival in germinal center-like diffuse large B-cell lymphoma, follicular lymphoma and classical Hodgkin’s lymphoma

  2008cited by this paper
• The biology of interleukin-2.

  2008cited by this paper
• Serum soluble interleukin 2 receptor α in human cancer of adults and children: a review

  2008cited by this paper
• High‐dose interleukin‐2 for the treatment of metastatic renal cell carcinoma

  2008cited by this paper
• Combination of the anti-CD30-auristatin-E antibody-drug conjugate (SGN-35) with chemotherapy improves antitumour activity in Hodgkin lymphoma

  2008cited by this paper
• Characterization of regulatory T cells in patients with B-cell chronic lymphocytic leukemia.

  2008cited by this paper
• Differential impact of mammalian target of rapamycin inhibition on CD4+CD25+Foxp3+ regulatory T cells compared with conventional CD4+ T cells.

  2008cited by this paper
• Immunosuppressive strategies that are mediated by tumor cells.

  2007influential reference
• Naturally occurring regulatory T cells: recent insights in health and disease.

  2007cited by this paper
• Large-scale genetic fine mapping and genotype-phenotype associations implicate polymorphism in the IL2RA region in type 1 diabetes

  2007cited by this paper
• Anti-Tac (daclizumab, Zenapax) in the Treatment of Leukemia, Autoimmune Diseases, and in the Prevention of Allograft Rejection: A 25-Year Personal Odyssey

  2007influential reference
• Administration of a CD25-Directed Immunotoxin, LMB-2, to Patients with Metastatic Melanoma Induces a Selective Partial Reduction in Regulatory T Cells In Vivo1

  2007influential reference
• Prognostic impact of tumor infiltrating FOXP3 positive regulatory T cells in diffuse large B-cell lymphoma at diagnosis

  2007influential reference
• PTEN inhibits IL-2 receptor-mediated expansion of CD4+ CD25+ Tregs.

  2006cited by this paper
• Defective Activation of Protein Kinase C and Ras-ERK Pathways Limits IL-2 Production and Proliferation by CD4+CD25+ Regulatory T Cells1

  2006cited by this paper
• Interleukin‐10‐secreting type 1 regulatory T cells in rodents and humans

  2006cited by this paper
• Bruton’s Tyrosine Kinase and SLP-65 Regulate Pre-B Cell Differentiation and the Induction of Ig Light Chain Gene Rearrangement1

  2006influential reference
• Potential use of IL-2/anti-IL-2 antibody immune complexes for the treatment of cancer and autoimmune disease

  2006cited by this paper
• Outcome in Hodgkin's Lymphoma Can Be Predicted from the Presence of Accompanying Cytotoxic and Regulatory T Cells

  2005cited by this paper
• Inability of a Fusion Protein of IL-2 and Diphtheria Toxin (Denileukin Diftitox, DAB389IL-2, ONTAK) to Eliminate Regulatory T Lymphocytes in Patients With Melanoma

  2005cited by this paper
• Elevated levels of soluble interleukin-2 receptor in serum of patients with hematological or non-hematological malignancies.

  2005cited by this paper
• Molecular genetics of acute lymphoblastic leukemia.

  2005cited by this paper
• Reduced frequencies and suppressive function of CD4+CD25hi regulatory T cells in patients with chronic lymphocytic leukemia after therapy with fludarabine.

  2005cited by this paper
• CD4+ CD25+ regulatory T cells control the induction of antigen-specific CD4+ helper T cell responses in cancer patients.

  2005cited by this paper
• The Structure of Interleukin-2 Complexed with Its Alpha Receptor

  2005influential reference
• SJG-136 (NSC 694501), a Novel Rationally Designed DNA Minor Groove Interstrand Cross-Linking Agent with Potent and Broad Spectrum Antitumor Activity

  2004cited by this paper
• SJG-136 (NSC 694501), A Novel Rationally Designed DNA Minor Groove Interstrand Cross-Linking Agent with Potent and Broad Spectrum Antitumor Activity

  2004cited by this paper
• Compensatory energetic mechanisms mediating the assembly of signaling complexes between interleukin-2 and its alpha, beta, and gamma(c) receptors.

  2004influential reference
• Two immunoglobulin G fragment C receptor polymorphisms independently predict response to rituximab in patients with follicular lymphoma.

  2003cited by this paper
• Immunophenotypic analysis of Waldenstrom's macroglobulinemia.

  2003cited by this paper
• Clinical advances in therapies targeting the interleukin-2 receptor.

  2003cited by this paper
• Effect of Anti‐IL‐2Rα Antibody on IL‐2‐induced Jak/STAT Signaling

  2002cited by this paper
• Pivotal phase III trial of two dose levels of denileukin diftitox for the treatment of cutaneous T-cell lymphoma.

  2001cited by this paper
• Topoisomerase I Inhibitors with an Indolocarbazole Structure Transporter as a Transporter of NB-506 and J-107088 , Resistance / Placenta-Specific , ATP-binding Cassette Identification of Breast Cancer Resistant Protein / Mitoxantrone Updated

  2001cited by this paper
• Serum soluble interleukin-2 receptor concentrations as an independent prognostic marker in head and neck cancer.

  2001cited by this paper
• Daclizumab (Zenapax) inhibits early interleukin-2 receptor signal transduction events.

  2000cited by this paper
• Clinical significance of serum soluble interleukin 2 receptor-alpha in esophageal squamous cell carcinoma.

  2000cited by this paper

• CD25-Targeted Aptamer-Drug Conjugate for the Treatment of CD25-Expressing Hematological Malignancies.

  2026cites this paper
• Flow cytometry as a predictive modality for translocation (9;22) and translocation (12;21) in B acute lymphoblastic leukemia

  2025cites this paper
• Transcriptomic characterization of human pancreatic CD206- and CD206 + macrophages

  2025cites this paper
• PF-08046032: A novel, investigational CD25-directed antibody-drug conjugate optimized for selective depletion of regulatory T cells in advanced malignant tumors.

  2025cites this paper
• SARS-CoV-2 vaccination unmasks distinct immune dysfunctions across lymphoma subtypes and therapies

  2025cites this paper
• Sleep Deprivation Alters T Cell Dynamics: Melatonin as a Restorative Agent.

  2025cites this paper
• Transient regulatory T cell manipulation is limited by anti-antibody responses in HIV-1 envelope immunized rhesus macaques

  2025cites this paper
• Durable response to an anti-CD25 antibody-drug conjugate and anti-PD-1 antibody in ovarian carcinoma: a case report.

  2025cites this paper
• PA28γ-containing tumor-derived exosomes promote T-cell dysfunction in head and neck squamous cell carcinoma

  2025cites this paper
• Interleukin-2 and Its Receptors: Implications and Therapeutic Prospects in Immune-Mediated Disorders of Central Nervous System.

  2025cites this paper
• A 4‐gene prognostic index for enhancing acute myeloid leukaemia survival prediction

  2024cites this paper
• Radiogenomic biomarkers for immunotherapy in glioblastoma: A systematic review of magnetic resonance imaging studies

  2024cites this paper
• Advances in Hodgkin Lymphoma Treatment: From Molecular Biology to Clinical Practice

  2024cites this paper
• Causal association between skin cancer and immune cells: mendelian randomization (MR) study

  2024cites this paper
• Targeting CD25+ lymphoma cells with the antibody–drug conjugate camidanlumab tesirine as a single agent or in combination with targeted agents

  2024cites this paper
• Identification of immunity- and ferroptosis-related signature genes as potential design targets for mRNA vaccines in AML patients

  2024cites this paper
• Non‐IL‐2‐blocking anti‐CD25 antibody inhibits tumor growth by depleting Tregs and has synergistic effects with anti‐CTLA‐4 therapy

  2024cites this paper
• The expression level of FOXP3 and CD25 in Iraqi patients with post burn injuries

  2023cites this paper
• New molecular targets in Hodgkin and Reed-Sternberg cells

  2023cites this paper
• Immunotherapy for Hodgkin lymphoma: from monoclonal antibodies to chimeric antigen receptor T-cell therapy.

  2023cites this paper
• CD25 targeting with the afucosylated human IgG1 antibody RG6292 eliminates regulatory T cells and CD25+ blasts in acute myeloid leukemia

  2023cites this paper
• Advances and challenges of immunotherapies in NK/T cell lymphomas

  2023cites this paper
• Classical Hodgkin Lymphoma: Tumor Structure and Prognostic Value of the Immune Microenvironment

  2023cites this paper
• Causal associations of cytokines and growth factors with cholelithiasis: a bidirectional Mendelian randomization study.

  2023cites this paper
• Developing Effective Cancer Vaccines Using Rendered-Inactive Tumor Cells

  2023cites this paper
• Identifying a prognostic model and screening of potential natural compounds for acute myeloid leukemia

  2023cites this paper
• Targeting CD25-positive lymphoma cells with the antibody-drug conjugate camidanlumab tesirine as single agent or in combination with targeted agents

  2023cites this paper
• Hub genes and their key effects on prognosis of Burkitt lymphoma

  2023cites this paper
• Population pharmacokinetics analysis of camidanlumab tesirine in patients with relapsed or refractory Hodgkin lymphoma and non-Hodgkin lymphoma

  2022cites this paper
• IL2RA is a prognostic indicator and correlated with immune characteristics of pancreatic ductal adenocarcinoma

  2022cites this paper
• Dampening of cytotoxic innate lymphoid cells: A new tumour immune escape mechanism in B cell non-Hodgkin's lymphoma.

  2022cites this paper
• Prognostic significance of CD25 expression in dogs with a noninvasive diagnosis of B-cell lymphoma treated with CHOP chemotherapy.

  2022cites this paper
• Perspective: Advances in liver transplantation for hepatocellular carcinoma - A prototype for transplant oncology.

  2022cites this paper
• CD25: A potential tumor therapeutic target

  2022cites this paper
• Immuno-PET Imaging and Radioimmunotherapy of Lymphomas.

  2022cites this paper
• Up-regulated serum levels of soluble CD25 and soluble CD163 in pediatric patients with SARS-CoV-2

  2022cites this paper
• Precision Medicine in Therapy of Non-solid Cancer.

  2022cites this paper
• Chasing leukemia differentiation through induction therapy, relapse and transplantation.

  2022cites this paper
• A Bright Horizon: Immunotherapy for Pediatric T-Cell Malignancies

  2022cites this paper
• Worked to the bone: antibody-based conditioning as the future of transplant biology

  2022cites this paper
• Dissecting Tissue Compartment-Specific Protein Signatures in Primary and Metastatic Oropharyngeal Squamous Cell Carcinomas

  2022cites this paper
• Successfully treated acute adult T-cell leukemia with haploidentical stem cell transplantation

  2022cites this paper
• Genetic Landscape of Peripheral T-Cell Lymphoma

  2022cites this paper
• Extensive Phenotypic Characterization of T Cells Infiltrating Liver Metastasis from Colorectal Cancer: A Potential Role in Precision Medicine

  2022cites this paper
• Integrative Analysis of Immune-Related Genes in the Tumor Microenvironment of Renal Clear Cell Carcinoma and Renal Papillary Cell Carcinoma

  2021cites this paper
• A New Target for Hodgkin Lymphoma - Camidanlumab Tesirine

  2021cites this paper
• Immunophenotype of Gastric Tumors Unveils a Pleiotropic Role of Regulatory T Cells in Tumor Development

  2021cites this paper
• Gene Expression–Based Prediction of Neoadjuvant Chemotherapy Response in Early Breast Cancer: Results of the Prospective Multicenter EXPRESSION Trial

  2021cites this paper
• Future directions in Hodgkin lymphoma: checkpoint inhibitors and beyond

  2021cites this paper
• Pseurotin D Inhibits the Activation of Human Lymphocytes

  2021cites this paper
• Novel therapies targeting cutaneous T cell lymphomas and their microenvironment.

  2021cites this paper
• Designing and generating a single-chain fragment variable (scFv) antibody against IL2Rα (CD25): An in silico and in vitro study

  2021cites this paper
• MiR-522-3p inhibits proliferation and activation by regulating the expression of SLC31A1 in T cells

  2021cites this paper
• Camidanlumab tesirine in patients with relapsed or refractory lymphoma: a phase 1, open-label, multicentre, dose-escalation, dose-expansion study.

  2021cites this paper
• Antibody-drug conjugates for the treatment of lymphoma: clinical advances and latest progress

  2021cites this paper
• Antibody–Drug Conjugates for the Treatment of Acute Pediatric Leukemia

  2021cites this paper
• Importance and Considerations of Antibody Engineering in Antibody-Drug Conjugates Development from a Clinical Pharmacologist’s Perspective

  2021cites this paper
• Transient regulatory T-cell targeting triggers immune control of multiple myeloma and prevents disease progression

  2021cites this paper
• Phase II study of pembrolizumab in refractory esophageal cancer with correlates of response and survival

  2021cites this paper
• Evaluation the Level of Interleukin 2 and 6’ Receptors in Hepatitis-C Patients in Wasit Province / Iraq

  2021cites this paper
• Quickly evolving near-infrared photoimmunotherapy provides multifaceted approach to modern cancer treatment

  2021cites this paper
• PANX1 is a potential prognostic biomarker associated with immune infiltration in pancreatic adenocarcinoma: A pan-cancer analysis

  2021cites this paper
• The relationship of GITR, Lag-3 and PD-1 expression with the main indicators of systemic and local immunity in patients with breast cancer

  2021cites this paper
• Nuclear Imaging of Endogenous Markers of Lymphocyte Response

  2021cites this paper
• PLGA nanodepots co-encapsulating prostratin and anti-CD25 enhance primary natural killer cell antiviral and antitumor function

  2020cites this paper
• Novel targeted therapies of T cell lymphomas

  2020cites this paper
• Recent updates for antibody therapy for acute lymphoblastic leukemia

  2020cites this paper
• CD4+CD25-FoxP3+ T cells: a distinct subset or a heterogeneous population?

  2020cites this paper
• CD25-targeted antibody–drug conjugate depletes regulatory T cells and eliminates established syngeneic tumors via antitumor immunity

  2020cites this paper
• IL2RA Promotes Aggressiveness and Stem Cell–Related Properties of Acute Myeloid Leukemia

  2020influential citation
• Therapeutic Zfra4-10 or WWOX7-21 Peptide Induces Complex Formation of WWOX with Selective Protein Targets in Organs that Leads to Cancer Suppression and Spleen Cytotoxic Memory Z Cell Activation In Vivo

  2020cites this paper
• PTEN Function at the Interface between Cancer and Tumor Microenvironment: Implications for Response to Immunotherapy

  2020cites this paper
• FoxP3+ T regulatory cells in cancer: Prognostic biomarkers and therapeutic targets.

  2020cites this paper
• Reduced polyfunctional T cells and increased cellular activation markers in adult allergy patients reporting adverse reactions to food

  2020cites this paper
• Camidanlumab tesirine, an antibody-drug conjugate, in relapsed/refractory CD25-positive acute myeloid leukemia or acute lymphoblastic leukemia: A phase I study.

  2020cites this paper
• The Resurgence of Antibody Drug Conjugates in Cancer Therapeutics: Novel Targets and Payloads.

  2020cites this paper
• Harnessing immunotherapy for pediatric T-cell malignancies

  2020cites this paper
• Development, analytical validation, and initial clinical evaluation of a radioimmunoassay for the measurement of soluble CD25 concentrations in canine serum.

  2019cites this paper
• Clinical Effect of CD25 on the Prognosis of Diffuse Large B Cell Lymphoma with Secondary Central Nervous System Relapse

  2019cites this paper
• TPD7 inhibits the growth of cutaneous T cell lymphoma H9 cell through regulating IL‐2R signalling pathway

  2019cites this paper
• Morphologic and Immunohistochemical Characterization of Spontaneous Lymphoma/Leukemia in NSG Mice

  2019cites this paper
• Cytokines frequently implicated in myeloproliferative neoplasms

  2019cites this paper
• Effects of interleukin-2 in immunostimulation and immunosuppression

  2019influential citation
• Electrochemical immunoassay for the tumor marker CD25 by coupling magnetic sphere-based enrichment and DNA based signal amplification

  2019cites this paper
• Cancer immunotherapy beyond immune checkpoint inhibitors

  2018cites this paper
• Precision Medicine and Toxicology

  2018cites this paper
• Notch and NF-κB: Coach and Players of Regulatory T-Cell Response in Cancer

  2018cites this paper
• Monoclonal Antibody Therapies for Hematological Malignancies: Not Just Lineage-Specific Targets

  2018cites this paper
• BP180 Is Critical in the Autoimmunity of Bullous Pemphigoid

  2017cites this paper
• Novel combination strategies for enhancing efficacy of immune checkpoint inhibitors in the treatment of metastatic solid malignancies

  2017cites this paper
• World Journal of Clinical Oncology

  year unknowncites this paper